We developed and validated a robust CCRG signature that effectively predicts prognosis, immune contexture, and therapeutic response in breast cancer. This signature offers novel insights into metabolic immunosuppression and provides a potential tool for risk stratification and personalized treatment strategies.
Fang et al. (Thu,) studied this question.